Defining Value-Based Pricing of Drugs Reply

被引：0
|
作者：
Kaltenboeck, Anna [1 ]
Bach, Peter B. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Ctr Hlth Policy & Outcomes, 485 Lexington Ave, New York, NY 10017 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2018年 / 320卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1001/jama.2018.11820
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1710 / 1711
页数：2
相关论文
共 50 条
  • [21] National value-based pricing negotiation for oncology drugs - lessons from China
    Yuan, Jing
    Li, Minghui
    Lu, Z. Kevin
    NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (08) : 501 - 502
  • [22] Multiple criteria qualitative value-based pricing framework " MARIE " for new drugs
    Takami, Akina
    Kato, Masafumi
    Deguchi, Hisato
    Igarashi, Ataru
    HEALTH POLICY AND TECHNOLOGY, 2024, 13 (06)
  • [23] Value-based pricing in professional sports
    Huefner R.J.
    Journal of Revenue and Pricing Management, 2017, 16 (1) : 30 - 39
  • [24] Implementation of Value-based Pricing for Medicines
    Jommi, Claudio
    Armeni, Patrizio
    Costa, Francesco
    Bertolani, Arianna
    Otto, Monica
    CLINICAL THERAPEUTICS, 2020, 42 (01) : 15 - 24
  • [25] Value-based pricing for medical education?
    Walsh, Kieran
    PAN AFRICAN MEDICAL JOURNAL, 2013, 16
  • [26] THE IMPACT OF VALUE-BASED PRICING (VBP) VS INTERNATIONAL REFERENCE PRICING (IRP) ON INNOVATIVE DRUGS IN THE US
    Labban, M.
    Patrick, A.
    Lederer, Mahendraratnam N.
    Jao, R.
    Patel, P.
    Jaksa, A.
    VALUE IN HEALTH, 2022, 25 (07) : S364 - S364
  • [27] Value-based Medicine Reply
    Brown, Melissa M.
    Brown, Gary C.
    Brown, Hgidi C.
    Peet, Jonathan
    OPHTHALMOLOGY, 2008, 115 (11) : 2100 - 2100
  • [28] Comment on: 'Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition'
    Garattini, Livio
    Freemantle, Nick
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2020, 18 (03) : 453 - 454
  • [29] Comment on: ‘Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition’
    Livio Garattini
    Nick Freemantle
    Applied Health Economics and Health Policy, 2020, 18 : 453 - 454
  • [30] Mindful pricing: transforming organizations through value-based pricing
    Liozu, Stephan
    Hinterhuber, Andreas
    Perelli, Sheri
    Boland, Richard
    JOURNAL OF STRATEGIC MARKETING, 2012, 20 (03) : 197 - 209
12345